Prostacyclin: a potent antimetastatic agent.
Metastasis is the principal cause of failures to cure human cancers. Prostacyclin is a powerful antimetastatic agent against B16 amelanotic melanoma cells. This effect, which may result from the platelet antiaggregatory action of prostacyclin, is potentiated by a phosphodiesterase inhibitor. Inhibitors of prostacyclin synthesis increase metastasis. Prostacyclin and agents that may increase endogenous prostacyclin production or prolong its activity are suggested as new antimetastatic agents.
D000818:Animals; D000970:Antineoplastic Agents; D011464:Epoprostenol / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008545:Melanoma / Q000188:drug therapy*; D051379:Mice; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011453:Prostaglandins / Q000627:therapeutic use*; D013806:Theophylline / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011453:Prostaglandins; D013806:Theophylline; D011464:Epoprostenol